Open-Label Clinical Trial to Evaluate the Effect of the Mico HPV Synbiotic Dietary Supplement on Vaginal and Intestinal Microbiota in HPV-Positive Patients
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 21
- 试验地点
- 1
- 主要终点
- Change in vaginal microbiota composition
研究概览
简要总结
This open-label, single-group study evaluated the effects of a 3-month oral synbiotic dietary supplement on vaginal and intestinal microbiota in women with a positive human papillomavirus (HPV) test. Vaginal and intestinal microbiota were assessed at baseline and after 3 months of supplementation. Secondary assessments included HPV clearance, vaginal health, safety and tolerability, and treatment adherence.
详细描述
Human papillomavirus infection has been associated with changes in the vaginal microbiota. The intestinal microbiota may also influence immune responses through the gut-vagina axis and could therefore be relevant to the persistence or clearance of HPV infection.
This was an exploratory, open-label, single-group interventional study in women aged 30 to 65 years with a positive HPV polymerase chain reaction test and either normal cervical cytology or cytological findings classified as atypical squamous cells of undetermined significance (ASC-US), low-grade squamous intraepithelial lesion (LSIL), or atypical glandular cells (AGC).
Participants received Papilozumib, an oral synbiotic dietary supplement, for 3 months. The recommended daily dose was three capsules: two capsules in the morning while fasting and one capsule before the midday meal.
Vaginal and intestinal microbiota samples were collected at baseline and at Month 3. Microbiota composition was assessed using shotgun metagenomic sequencing to characterize the relative abundance and distribution of microbial taxa. Vaginal microbiota assessment included characterization of Lactobacillus-dominated community state types. Intestinal microbiota assessment included taxonomic composition and selected microbial functional genes.
Secondary assessments included HPV status by polymerase chain reaction, vaginal health measured using the Bachmann Vaginal Health Index, adverse events and tolerability, and adherence based on product-dispensing records. Safety evaluations included physical and gynecological examinations, vital signs, anthropometric measurements, and review of concomitant medications.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 30 Years 至 65 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female, aged 30 to 65 years, inclusive.
- •Able to read and understand the Participant Information Sheet and Informed Consent Form.
- •Willing to participate in the study and provide written informed consent.
- •Normal cervical cytology or cytological findings of atypical squamous cells of undetermined significance (ASC-US), low-grade squamous intraepithelial lesion (LSIL), or atypical glandular cells (AGC), confirmed no more than 3 months before the screening visit.
- •Positive human papillomavirus (HPV) polymerase chain reaction test performed at the screening visit or available from no more than 3 months before the baseline visit.
- •Able, in the investigator's judgment, to comply with the study requirements and follow the study instructions and assessments.
排除标准
- •Clinically relevant immune system disorder, autoimmune disease, or current treatment with immunosuppressive agents.
- •Systemic or local antibiotic, antifungal, or other treatment capable of altering the microbiota within 4 weeks before study treatment initiation.
- •Undiagnosed abnormal genital bleeding within 6 months before the screening visit.
- •Symptomatic vulvovaginal infection.
- •Previous history of gynecological cancer.
- •Current participation in another clinical trial or participation in another clinical trial within 4 weeks before study inclusion.
- •Planned surgery that could prevent adherence to the study treatment regimen.
- •Use of vaginal contraceptives or other vaginal hormonal treatments.
- •Contraindication to the synbiotic dietary supplement or known allergy to any of its components.
- •Woman of childbearing potential not using effective contraception, pregnancy, suspected pregnancy, or breastfeeding.
研究组 & 干预措施
Papilozumib
Participants received Papilozumib, an oral synbiotic dietary supplement, for 3 months. The recommended daily dose was three capsules: two capsules in the morning while fasting and one capsule before the midday meal.
干预措施: Papilozumib (Dietary Supplement)
结局指标
主要结局
Change in vaginal microbiota composition
时间窗: Baseline and Month 3
Change from baseline in the composition of the vaginal microbiota, assessed by shotgun metagenomic sequencing. The assessment includes the relative abundance and distribution of vaginal microbial taxa and characterization of Lactobacillus-dominated community state types.
Change in intestinal microbiota composition
时间窗: Baseline and Month 3
Change from baseline in the composition of the intestinal microbiota, assessed by shotgun metagenomic sequencing. The assessment includes the relative abundance and distribution of intestinal microbial taxa, microbial diversity using the Shannon index, and the abundance of 22 prespecified microbial functional genes.
次要结局
- HPV clearance at Month 3(Baseline and Month 3)
- Change in Bachmann Vaginal Health Index score(Baseline and Month 3)
- Number of participants with adverse events(From the first dose through Month 3)
- Treatment adherence based on dispensing records(From baseline through Month 3)